Kenji Osafune

USPTO Granted Patents = 12 (Patent Applications = 18)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 9 (Patent Applications = 21)

Average Co-Inventor Count = 2.7

ph-index = 2

Forward Citations = 15(Granted Patents)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2015-2023

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11821007 - Method for inducing differentiation of intermediate mesodermal cell to renal progenitor cell, and method for inducing differentiation of pluripotent stem cell to renal progenitor cell (2023-11-21),

2. 11746332 - Method for producing renal progenitor cells (2023-09-05),

3. 11225642 - Method for producing renal progenitor cells (2022-01-18),

4. 10961508 - Method for inducing alveolar epithelial progenitor cells (2021-03-30),

5. 10731133 - Method for producing renal progenitor cells (2020-08-04),

6. 10711249 - Method for inducing hepatocytes (2020-07-14),

7. 10472610 - Method for generating pancreatic bud cells and therapeutic agent for pancreatic disease containing pancreatic bud cells (2019-11-12),

8. 9902938 - Method for inducing exocrine pancreatic cells (2018-02-27),

9. 9890357 - Method for inducing differentiation of human pluripotent stem cells into intermediate mesoderm cells (2018-02-13),

10. 9796962 - Method for generating pancreatic hormone-producing cells (2017-10-24),

11. 9334475 - Method for inducing erythropoietin-producing cell (2016-05-10),

12. 9121011 - Method for inducing differentiation of human pluripotent stem cell into intermediate mesoderm cell (2015-09-01),

Title: Innovator Kenji Osafune: Pioneering Advances in Renal Progenitor Cell Research

Introduction

Kenji Osafune is a renowned inventor based in Kyoto, Japan, known for his groundbreaking contributions in the field of regenerative medicine. With an impressive portfolio of 12 patents, Osafune's research focuses primarily on the differentiation of pluripotent stem cells into renal progenitor cells, which holds significant potential for treating renal diseases.

Latest Patents

Two of Kenji Osafune's latest patents include innovative methods for inducing the differentiation of both intermediate mesodermal cells and pluripotent stem cells to renal progenitor cells. The first method outlines a detailed protocol involving the culture of pluripotent stem cells in mediums enriched with FGF2, BMP4, a GSK-3β inhibitor, and retinoic acid or its derivatives. This process enables the subsequent cultivation of these cells in different media formations, ultimately leading to the successful production of renal progenitor cells from intermediate mesodermal cells. The second patent describes methods to acquire high-purity renal progenitor cells, targeting specific cell surface antigens to refine the cell population. These advancements are crucial for the future of regenerative treatments for conditions like renal failure.

Career Highlights

Kenji Osafune has made noteworthy strides during his academic and professional career, particularly while collaborating with institutions like Kyoto University and Astellas Pharma GmbH. His commitment to enhancing stem cell research continues to pave the way for innovative therapies that directly address kidney health challenges.

Collaborations

Throughout his journey, Osafune has had the opportunity to work alongside esteemed colleagues such as Yukiko Yamagishi and Taro Toyoda. These collaborations enrich his research and contribute to the collective advancement of knowledge in the field of regenerative medicine.

Conclusion

Kenji Osafune's trailblazing work in the realm of renal progenitor cell differentiation underscores his commitment to innovation within medical science. As he continues to develop novel methods and refine existing techniques, his contributions promise to significantly impact the landscape of medical treatments for renal diseases and beyond.

This text is generated by artificial intelligence and may not be accurate.